Solventum saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 79 to 85.
IBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating of over 80 as they begin their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Solventum is trying to complete a cup with handle with a 76.80 buy point. See if the stock can clear the breakout price in heavy volume.
The company posted -43% earnings growth in its most recent report, while sales growth came in at 0%. The company is expected to report its latest earnings and sales numbers on or around Feb. 27.
Solventum earns the No. 35 rank among its peers in the Medical-Products industry group. Boston Scientific, LeMaitre Vascular and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
